2026 Medicaid MCO formulary trends: which states added Zepbound or Wegovy following CMS’s new obesity treatment coverage guidance
Obesity drug coverage in Medicaid managed care organizations (MCOs) shifted fast after the Centers for Medicare & Medicaid Services (CMS) issued late-2025 guidance clarifying that GLP-1 receptor agonists for chronic weight management could qualify for federal matching funds when medically necessary. By early 2026, several state Medicaid programs had moved to include either Zepbound (tirzepatide, from Eli Lilly) or Wegovy (semaglutide, from Novo Nordisk) on their formularies.
Q4 2025, CMS guidance and state planning
In December 2025, CMS sent a letter to state Medicaid directors allowing more flexibility for covering GLP-1 drugs approved for both type 2 diabetes and obesity. It drew a direct line between obesity and long-term metabolic health, giving states a tangible fiscal reason to revisit long-standing exclusions for weight-loss therapy. MCOs jumped into actuarial modeling almost immediately, knowing that 2026 rate filings would need to reflect new pharmacy benefits.
According to KFF Health News reporting in May 2026, affordability concerns still shaped how both states and insurers made decisions. Medicaid plans realized that excluding drugs with major downstream potential, less diabetes, fewer heart issues, risked higher long-term costs. That recognition sped up the review cycles for adding these GLP-1 drugs.
January-March 2026, early adopters implement coverage
By January, at least seven states had already revised MCO contracts to cover one or both drugs. North Carolina, Michigan, and California led the pack. Medicaid plans there listed Wegovy as a nonpreferred Tier 4 brand, typically requiring prior authorization for people with a BMI above 35 kg/m² or additional comorbidities. Tirzepatide landed on preferred specialty tiers when prescribed for patients who had used Mounjaro for diabetes and were transitioning to Zepbound for obesity management.
State actuaries pegged per-member cost increases at roughly $12-$18 each month if uptake was high. But February data showed only modest adoption. Why? Some doctors hesitated to prescribe, and step-therapy rules slowed things down. Same story, different state.
April-June 2026, broader adoption and formulary harmonization
Spring brought a second wave. Illinois, Oregon, and Pennsylvania adopted similar formulary language mentioning “anti-obesity agents with GLP-1 receptor activity.” Either semaglutide 2.4 mg (Wegovy) or tirzepatide 5-15 mg (Zepbound) became eligible under Medicaid MCO coverage with clearer authorization criteria. Typically, that meant proof of prior participation in a structured weight program and documentation of at least 5% weight loss within six months to keep the medication approved.
Smaller states like Vermont and Delaware sat tight. They pushed implementation to the 2027 rate cycle while sorting through rebate logistics with manufacturers. PBMs advising these states said the rebate math could shift the overall cost curve significantly, depending, of course, on how negotiations played out.
Comparative overview of 2026 state Medicaid MCO coverage
| State | Drug Name (brand/generic) | Manufacturer | Tier Placement | Effective Date |
|---|---|---|---|---|
| North Carolina | Wegovy (semaglutide) | Novo Nordisk | Tier 4, prior authorization | Jan 2026 |
| Michigan | Zepbound (tirzepatide) | Eli Lilly | Preferred specialty tier | Feb 2026 |
| California | Wegovy (semaglutide) | Novo Nordisk | Tier 4, nonpreferred | Mar 2026 |
| Illinois | Zepbound (tirzepatide) | Eli Lilly | Tier 3, limited preferred | Apr 2026 |
| Pennsylvania | Wegovy (semaglutide) | Novo Nordisk | Tier 3, with weight program condition | May 2026 |
Summer 2026, patient access and coverage equity debates
By midyear, the conversation moved from simple cost math to fairness. Patient advocates, echoing those quoted in STAT News, described “ghost approval”, coverage policies that looked generous but rarely converted into filled prescriptions. Many members still hit slow prior authorizations or supply delays at pharmacies. MCOs started revising turnaround times and appeal steps, trying to make the benefit actually usable.
Analysts viewed 2026 as a turning point. Medicaid programs were finally treating obesity like a chronic disease instead of a lifestyle issue. Whether these shifts reduce long-term costs or actually improve outcomes remains an open question. Data from 2027’s utilization reviews should tell us more, assuming states keep publishing those reports, anyway.
Medical and insurance disclaimer: This article provides general policy information and does not constitute medical advice or legal guidance. Patients should consult clinicians for treatment decisions, and plan administrators should verify state-specific formulary listings before implementation.